Why Clinical Trial Plain Language Summaries Get Rejected – And How to Get Them Right the First Time

How can the same plain language summary pass regulatory review in Ireland, but get rejected in Germany for “oversimplification”, while France sends it back because of “unnatural phrasing”?

If you’re coordinating clinical trial transparency across multiple EU markets, you’ve probably encountered this. The Annex V structure is identical. The clinical data hasn’t changed. What differs is the way each regulatory authority interprets what makes language genuinely “plain” for patients in their market.

ICH E6(R3) makes plain language summaries mandatory for all clinical trials. EU CTR 536/2014 specifies the Annex V structure requirements. But neither document tells you exactly how “plain” should look in German versus French versus Dutch, or what evidence that your summary is actually understandable to patients each authority expects to see.

That gap between regulatory mandate and country-specific expectations is where submission timelines get derailed.

Why BfArM, ANSM, and HRA Read “Plain Language” Differently

Germany’s BfArM expects scientific precision to be maintained even in explanations of mechanisms written using everyday language. If you simplify texts too aggressively by removing qualifiers, then you’ll get feedback about oversimplification. They want “may cause dizziness in some patients” rather than “causes dizziness” because the qualifier matters for accuracy.

France’s ANSM reads with natural French flow front of mind. A technically accurate word-for-word translation from English won’t satisfy their reviewers if it sounds like a translated text. They expect restructured sentences that follow French syntax patterns, proper typographic conventions (space before colons and semicolons, guillemets instead of English quotation marks), and phrasing that sounds natural to French patients.

The UK’s HRA wants documented evidence of readability validation. Which metrics did you use? What patient feedback did you receive? What changes did you make based on that feedback? Claims that the text is readable are not enough, they expect to see your methodology documented.

These expectations reflect each country’s regulatory culture and national health literacy standards. Understanding them before you submit prevents you from getting stuck in the clarification-revision-resubmission cycle that delays CTIS publication.

Image by Drazen Zigic on Freepik

The 12 Patterns That Trigger Regulatory Feedback

Having handled submissions for CROs and Clinical Trial Transparency Providers across multiple countries, we’ve identified 12 recurring rejection patterns:

• Undefined specialist terms create problems when technical language appears without plain-language equivalents, or when terms get explained once but are then used without further definition later in the document.
• Safety information placement triggers feedback when the details of risks are nested inside results sections instead of having dedicated, clearly labeled sections that patients can find easily.
• Over-simplified risk wording removes layers of meaning when qualifiers like “may” or “could” get stripped out. What seems like simplifying a text actually removes the precision that regulators need preserved.
• Terminology inconsistency happens when the same concept gets called different things in different sections. For example, one section refers to “harmful side effects that require hospitalization” while another uses “serious unwanted reactions” to refer to the same concept. Or the French version translates a term one way in section 2, and differently in section 5.
• Locale formatting errors include using decimal points instead of commas in German submissions, applying US date formats (MM/DD/YYYY) to markets expecting DD/MM/YYYY, or ignoring French typographic spacing rules.
• Unclear numeracy presents statistics without context. “15% of participants experienced headache” needs explanation: “about 15 out of every 100 people had headaches.”

The remaining six patterns include using a promotional tone that suggests benefit claims, using dense paragraph blocks without introducing adequate white space, using undefined acronyms, deviating from Annex V structure, including CTIS metadata that doesn’t match the summary content, and failing to include documentation of the readability validation methods used. Most of these are preventable when you know what each market prioritizes before submission.

What Country-Specific Preparation Actually Looks Like

The plain language summary challenges we see most often aren’t related to translation accuracy in the traditional sense. Clients receive feedback from multiple markets flagging terminology inconsistencies, locale formatting issues, or structural concerns – even when the translations technically followed Annex V requirements.

What‘s missing is regulatory intelligence about what each authority expects when reviewing plain language summaries.

We approach this by building glossaries that ensure terminology stays consistent throughout the document and across all language versions. We create a locked glossary that maps each technical term to a single plain-language equivalent.

For example:
‘Serious adverse event’ becomes ‘serious medical problem that happens during the study and usually needs hospital care or urgent treatment, whether or not it is caused by the study treatment’.

That exact phrasing appears consistently in every section and every language version.

We run dedicated locale QA passes for each market, such as decimal commas for Germany, French typographic spacing rules, and Italian date formatting conventions.

We help clients assemble Evidence Packs documenting their readability validation process, like which metrics they used, what patient feedback they incorporated, what terminology decisions they made, and why.

Why Regulatory Experience Makes a Measurable Difference

Our network includes over 200 specialized linguists, many with regulatory affairs backgrounds in clinical trials, medical devices, and pharma. When they localize a plain language summary for Germany, they understand that BfArM reviewers expect qualifiers to remain intact when mechanisms are explained in everyday terms.

Those specializing in France know ANSM wants sentences restructured to reflect natural French flow rather than using English syntax with French vocabulary. They apply market-specific typographic and formatting conventions because these details matter to reviewers who are evaluating dozens of submissions.

This regulatory intelligence comes from direct experience with authority-specific review processes. We handle submissions for CROs coordinating multi-country trials, work on disclosure packages that include plain language summaries, and collaborate with other language service providers as specialized partners on complex regulatory programs.

The practices that consistently reduce the risk of rejection include glossaries that are locked before localization starts, separate locale QA passes for each market, and documented readability validation with concrete evidence.

Building Submissions That Pass First Review

There are three core practices that separate submissions that clear regulatory review first time from those that need revision cycles:

1. Terminology discipline starts before translation. Create a versioned glossary matching technical terms with lay equivalents. Lock this glossary before linguists work with the source document. Then, run a final cross-check across all sections and languages to catch any inconsistencies before submission.
2. Country-specific locale QA runs as dedicated passes. Don’t assume formatting transfers from English source documents. Germany and France use decimal commas. Belgian submissions need separate Dutch and French reviews, with zero terminology bleed between versions. Polish requires attention to case inflection patterns that English doesn’t have. Make these separate QA steps rather than expecting translators to catch them during localization.
3. Evidence Pack documentation goes with submissions. Document which readability metrics you used, what patient feedback you received, and what terminology decisions you made and why. Provide confirmation that locale formatting was verified for each market. Regulators reviewing multiple submissions appreciate seeing your quality process documented upfront rather than having to request clarification.

When these practices get integrated into workflow milestones and project timelines, you avoid delays that push back publication dates and multiply revision costs.

Getting Plain Language Summaries Right the First Time

Clinical trial plain language summaries call for more than just language translation. They need linguists who understand country-specific regulatory expectations: what ANSM considers acceptable French plain language versus what BfArM expects in German summaries, or what evidence HRA wants documented to validate English readability.

We’ve spent over 25 years building regulatory expertise across the life sciences, information technology, and engineering sectors. Our country-specific preparation approach helps teams avoid rejection patterns that may delay approvals and increase costs.

What challenges are you facing with your next clinical trial plain language summary submission?

Let’s discuss how we can help.

Whether you’re coordinating submissions for a multi-country trial or preparing disclosure packages, we’d be glad to explore how our regulatory intelligence and locale expertise could support your timeline.

Download our EU+UK country matrix with regulator-specific expectations, formatting requirements, and submission best practices for all 12 major markets.